| Project/Area Number |
26870527
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor therapeutics
Biological pharmacy
|
|---|
| Research Institution | Tohoku Pharmaceutical University |
|---|
Principal Investigator |
TATSUTA Takeo 東北薬科大学, 薬学部, 助教 (70438563)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Keywords | リボヌクレアーゼ / レクチン / 抗腫瘍作用 / 抗がん作用 / 分子生物学 |
|---|
| Outline of Final Research Achievements |
A sialic acid-binding lectin derived from Bullfrog eggs (SBL) has both lectin and ribonuclease activity. It has been revealed that SBL demonstrates anti-tumor effect. In this time, we constructed recombinant proteins of SBL and other antitumor ribonucleases and performed cross-link experiments to identify their receptor-like molecules . Furthermore, we assessed anti-tumor effect of SBL against several malignant mesothelioma cell lines.
As a result, the actin has identified as the receptor-like molecule candidate . Furthermore, SBL exhibited more wide-ranging and cancer cell selective anti-tumor effect compared to existing drug such as pemetrexed. And also, combination treatment of SBL and pemetrexed showed synergistic anti-tumor effect. These results indicate that SBL could be a novel kind of anti-cancer drug.
|
